Faron

📍 Turku, Finland🗓 Founded 2007👥 38 employees💰 Last funded Mar 2020
Pharmaceutical Manufacturing🌐 faron.com
Website LinkedIn
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
2007
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United Kingdom
1
Finland
1
Frequently asked questions
Who invested in Faron?
Faron has 2 investors on record on gritt.io and 1 late-stage investors.
When did Faron last raise funding?
The most recent investment in Faron recorded on gritt.io was in March 2020.
When was Faron founded?
Faron was founded in 2007.
What industry is Faron in?
Faron operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Faron based?
Faron is headquartered in Turku, Finland.